Enliven Therapeutics (NASDAQ:ELVN) Releases Earnings Results, Beats Expectations By $0.06 EPS

Enliven Therapeutics (NASDAQ:ELVN) announced its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06, FiscalAI reports.

Enliven Therapeutics Trading Up 1.1%

Shares of ELVN stock traded up $0.46 during trading hours on Friday, reaching $40.75. 606,389 shares of the company’s stock were exchanged, compared to its average volume of 742,574. The stock’s 50 day moving average is $37.05 and its 200-day moving average is $27.33. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -24.40 and a beta of 0.32. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $48.53.

Insiders Place Their Bets

In other news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director directly owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 10,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total value of $295,800.00. Following the transaction, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently made changes to their positions in ELVN. BNP Paribas Financial Markets grew its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter valued at $83,000. Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Enliven Therapeutics during the fourth quarter valued at $191,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. The Goldman Sachs Group boosted their price objective on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 3rd. Finally, Mizuho boosted their price objective on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enliven Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $47.80.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.